DXR Daxor
- 9.881
- +0.081+0.82%
Daxor News
New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation
Daxor's Promising Growth and Innovation Outlook Merit a Buy Rating
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
450-Bed Hospital Purchases BVA-100 Blood Volume Analyzer to Launch Heart Failure Program Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American Col
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript
Daxor(DXR.US) Officer Buys US$6,525 in Common Stock
$Daxor(DXR.US)$ Officer Michel Robert J purchased 750 shares of Common Stock on Mar 27, 2024 at an average price of $8.7 for a total value of $6,525.Source: Announcement What is statement of changes i
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)
Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics
Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m.
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in bl
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients
Only Daxor's BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood
Daxor(DXR.US) Director Buys US$7,210 in Common Stocks
$Daxor(DXR.US)$ Director Feuer Edward purchased 1,000 shares of Common Stocks on Mar 4, 2024 at an average price of $7.21 for a total value of $7,210.Source: Announcement What is statement of changes
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Technology an
Daxor Announces Two Significant New Customer Transactions With The Co's BVA-100 In January; No Financial Terms Disclosed
Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor's BVA-100 (Blood Volume Analyzer) in Janua
Daxor Corporation Starts 2024 With Ongoing Growth in New Blood Volume Analyzer Acquisitions
Daxor Corporation Closes Q4 2023 With Growth in New Sales to Hospital Systems and Increased Utilization of Its BVA-100 Blood Volume Diagnostic Across the U.S. at Existing Accounts
Daxor's ezBVA Lab Service Plays a Significant Role in Driving Growth and Fostering Widespread Adoption Oak Ridge, TN, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nu
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress
Oak Ridge, TN, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for C
Daxor Announces That The United States Patent And Trademark Office Has Issued The Company A Second Patent, Safeguarding A Distinctive Clinical Guidance System For Blood Volume Management
This System Utilizes Unique Blood Volume Metrics And Related Clinical Measures To Create Support Guidance For Fluid Management Interventions
Analysis
Price Target
No Data
